Experts highlight the potential of under-utilised treatments like monoamine oxidase inhibitors while examining emerging ...

IOWA CITY, Iowa — University of Iowa Health Care is making progress helping those suffering with depression and obsessive ...

- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, ...

Ketamine has promise as a potential treatment for bipolar depression, particularly for people whose condition hasn’t ...

Elon Musk discussed his use of ketamine for depression during an interview, claiming it helps him combat negative mental ...

The allegations concerning Elon Musk’s personal use of ketamine and other substances should be viewed with caution and ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing ...

atai Life Sciences initiates Phase 2 trial for VLS-01, a treatment for treatment-resistant depression, with results expected in 2026. Atai Life Sciences has initiated the Phase 2 Elumina trial to ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief that rapid-acting psychedelics like 5-MeO-DMT have the ...

"Millions worldwide struggle with treatment-resistant depression, often left with few or no viable options. With VLS-01, we see the potential to offer rapid, robust, and durable antidepressant ...